NCT04665739 2026-04-16
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
19 trialsNCT05749588 2026-04-16
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Phase 2 Recruiting
NCT06955169 2026-04-16
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT05773274 2026-04-15
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07340541 2026-04-13
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06428396 2026-03-24
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT06126588 2025-03-11
ELUMEN
Central Hospital, Nancy, France
Phase 2 Recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT04803318 2024-06-25
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT05949541 2024-02-08
BCTOP-L-M01
Fudan University
Phase 2 Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT05983107 2023-08-09
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting